Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
IRVINE, Calif. and AMSTERDAM, Aug. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The conference is one of several events organized by Agendia throughout the year that brings together research scientists and physicians in clinical practice dedicated to the use and development of molecular diagnostics for cancer treatment.
"Events like these demonstrate why it is an exciting time in the field of medical oncology," said Dr. Stefan Gluck, Chairman of Agendia's Medical Advisory Board. "Breakthrough tools in molecular diagnostics, such as Agendia's MammaPrint, BluePrint and ColoPrint, play an integral role in helping physicians make clinical decisions about how to most effectively treat their patients. Most importantly, these tools are only the beginning of the precision medicine revolution."
The event featured an impressive list of speakers and panels on the following topics:
The Science Behind Genomic Based Analysis of Breast Cancer
- Rene Bernards, PhD
Chief Scientific Officer and Co-Founder, Agendia
Clinical Utility of Molecular Diagnostics
- Ralph V. Boccia, MD, FACP
Clinical Associate Professor of Medicine, Georgetown University
Landmark Clinical Trials
- Stefan Gluck, MD, FRCP(C), PhD
Sylvester Professor, Miller School of Medicine, University of Miami
Tumor Round Table Discussion and Case Study Review